Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine

Current Pharmaceutical Design

Volumn 20, Issue 14, 2014, Pages 2275-2292

  Altai, Mohamed ^a   Orlova, Anna ^b   Tolmachev, Vladimir ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Molecular imaging; Monoclonal antibodies; Radionuclide; Receptor tyrosine kinases; Scaffold proteins; Tyrosine kinase inhibitors

Indexed keywords

AFATINIB; ANKYRIN; BEVACIZUMAB; CEDIRANIB; CETUXIMAB; DASATINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR; ERLOTINIB; FIBRONECTIN; GEFITINIB; IMATINIB; LAPATINIB; LUMINESPIB; MONOCLONAL ANTIBODY; NANOBODY; NERATINIB; NVP AEW 541; OLARATUMAB; PANITUMUMAB; PAZOPANIB; PROTEIN TYROSINE KINASE; RAMUCIRUMAB; SCAFFOLD PROTEIN; SOMATOMEDIN; SORAFENIB; SUNITINIB; TANESPIMYCIN; TRASTUZUMAB; VASCULOTROPIN; ANTINEOPLASTIC AGENT; FLUORESCENT DYE; PROTEIN KINASE INHIBITOR; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER THERAPY; DRUG TARGETING; HUMAN; HYDROPHOBICITY; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; NEOPLASM; NONHUMAN; PERSONALIZED MEDICINE; PHAGE DISPLAY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DIAGNOSTIC USE; DRUG DELIVERY SYSTEM; METABOLISM; NEOPLASMS; PROCEDURES; SCINTISCANNING;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; FLUORESCENT DYES; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; PROTEIN KINASE INHIBITORS; RADIOPHARMACEUTICALS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84903704722     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113196660667     Document Type: Article

References (254)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
2. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141: 1117-34.
3. Lin SY, Makino K, Xia W, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001; 3: 802-8.
4. Grassot J, Mouchiroud G, Perrière G. RTKdb: database of Receptor Tyrosine Kinase. Nucleic Acids Res 2003; 31: 353-8.
5. Leppänen VM, Prota AE, Jeltsch M, et al. Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proc Natl Acad Sci USA 2010; 107: 2425-30.
6. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211-25.
7. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-84.
8. Sharma PS, Sharma R, Tyagi T. Receptor tyrosine kinase inhibitors as potent weapons in war against cancers. Curr Pharm Des 2009; 15: 758-76.
9. Wong KK. Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway. Recent Pat Anticancer Drug Discov 2009; 4: 28-35.
10. Gilmartin AG, Bleam MR, Groy A, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011; 17: 989-1000.
11. Arkenau HT, Kefford R, Long GV. Targeting BRAF for patients with melanoma. Br J Cancer 2011; 104: 392-8.
12. Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
13. Karp DD, Paz-Ares LG, Novello S, et al. Phase II study of the antiinsulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009; 27: 2516-22.
14. Bailey TA, Luan H, Clubb RJ, et al. Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance. J Carcinog 2011; 10: 28.
15. Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther 2011; 11: 777-92.
16. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005; 23: 1137-46.
17. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1: 118-29.
18. Mathew J, Perez EA. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. Curr Opin Oncol 2011; 23: 594-600.
19. FDA approved drug products data base www.accessdata.fda.gov.
20. Pytel D, Sliwinski T, Poplawski T, Ferriola D, Majsterek I. Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem 2009; 9: 66-76.
21. Giaccone G, Wang Y. Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat Rev 2011; 37: 456-64.
22. Wang YC, Morrison G, Gillihan R, et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation. Breast Cancer Res 2011; 13: R121.
23. Miranda C, Nucifora M, Molinari F, et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res 2012; 18: 1769-76.
24. Daub H, Specht K, Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 2004; 3: 1001-10.
25. Lierman E, Folens C, Stover EH, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006; 108: 1374-6.
26. Guida T, Anaganti S, Provitera L, et al. Sorafenib inhibits imatinibresistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res 2007; 13: 3363-9.
27. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med.2005; 2: e73.
28. Pallis A, Briasoulis E, Linardou H, et al. Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations. Curr Med Chem 2011; 18: 1613-28.
29. Hurbin A, Wislez M, Busser B, et al. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. J Pathol 2011; 225: 83-95.
30. Burke HB, Henson DE. The American Joint Committee on Cancer. Criteria for prognostic factors and for an enhanced prognostic system. Cancer 1993; 72: 3131-5.
31. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
32. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707-12.
33. Pegram MD, Pienkowski T, Northfelt DW, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004; 96: 759-69.
34. Burstein HJ, Storniolo AM, Franco S, et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008; 19: 1068-74.
35. Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008; 26: 5544-52
36. Koh Y, Lee HE, Im SA, et al. VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib. Diagn Mol Pathol 2011; 20: 143-7.
37. Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012; 13: 33-42.
38. Mascaux C, Wynes MW, Kato Y, et al. EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology. Clin Cancer Res 2011; 17: 7796-807.
39. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65: 11118-28.
40. Zha J, O'Brien C, Savage H, et al. Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther 2009; 8: 2110-21.
41. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-45.
42. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996; 13: 63-72.
43. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002; 20: 3095-105.
44. Bartlett JM, Going JJ, Mallon EA, et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 2001; 195: 422-8.
45. Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and repro ducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res.2005; 11: 6598-607.
46. Rhodes A, Jasani B, Anderson E, Dodson AR, Balaton AJ. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol 2002; 118: 408-17.
47. Dybdal N, Leiberman G, Anderson S, et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005; 93: 3-11.
48. Penault-Llorca F, Bilous M, Dowsett M, et al. Emerging technologies for assessing HER2 amplification. Am J Clin Pathol 2009; 132: 539-48.
49. Larson JS, Goodman LJ, Tan Y, et al. Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens. Patholog Res Int 2010; 2010: 814176.
50. Rosa FE, Silveira SM, Silveira CG, et al. Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma. BMC Cancer 2009; 9: 90.
51. Bravaccini S, Rengucci C, Medri L, Zoli W, Silvestrini R, Amadori D. Detection of HER2 and Topo 2 in breast cancers: comparison between MLPA and FISH approaches. J Clin Pathol 2012; 65: 183-5.
52. Farshid G, Cheetham G, Davies R, Moore S, Rudzki Z. Validation of the multiplex ligation-dependent probe amplification (MLPA) technique for the determination of HER2 gene amplification in breast cancer. Diagn Mol Pathol 2011; 20: 11-7.
53. Dei Tos AP, Ellis I. Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods? Eur J Cancer 2005; 41: 1383-92.
54. Apple SK, Lowe AC, Rao PN, Shintaku IP, Moatamed NA. Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer. Mod. Pathol 2009; 22: 1151-9.
55. Koda M, Sulkowski S, Garofalo C, Kanczuga-Koda L, Sulkowska M, Surmacz E. Expression of the insulin-like growth factor-I receptor in primary breast cancer and lymph node metastases: correlations with estrogen receptors alpha and beta. Horm Metab Res 2003; 35: 794-801.
56. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004; 22: 4772-8.
57. Fehm T, Krawczyk N, Solomayer EF, et al. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res 2008; 10: R76.
58. Rasbridge SA, Gillett CE, Seymour AM, et al. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 1994; 70: 335-41.
59. Choong LY, Lim S, Loh MC, et al. Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in target-directed therapeutics. Mol Cancer Ther 2007; 6: 2828-42.
60. Lam L, McAndrew N, Yee M, Fu T, Tchou JC, Zhang H. Challenges in the clinical utility of the serum test for HER2 ECD. Biochim Biophys Acta 2012; 1826: 199-208.
61. Lennon S, Barton C, Banken L, et al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol 2009; 27: 1685-93.
62. Hartkopf AD, Banys M, Fehm T. HER2-Positive DTCs/CTCs in Breast Cancer. Recent Results Cancer Res 2012; 195: 203-15.
63. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
64. Contractor KB, Aboagye EO. Monitoring predominantly cytostatic treatment response with 18F-FDG PET. J Nucl Med 2009; 50 Suppl 1: 97S-105S.
65. Shepherd FA, Rodrigues Pereira J, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32.
66. Weber WA. Assessing tumor response to therapy. J Nucl Med 2009; 50 Suppl 1: 1S-10S.
67. Mozley PD, Bendtsen C, Zhao B, et al. Measurement of Tumor Volumes Improves RECIST-Based Response Assessments in Advanced Lung Cancer. Transl Oncol 2012; 5: 19-25.
68. Frauenfelder T, Tutic M, Weder W, et al. Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma? Eur Respir J 2011; 38: 162-8.
69. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753-9.
70. Cousin S, Taieb S, Penel N. A paradigm shift in tumour response evaluation of targeted therapy: the assessment of novel drugs in exploratory clinical trials. Curr Opin Oncol 2012; 24: 338-44.
71. Nishino M, Jagannathan JP, Krajewski KM, et al. Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol 2012; 198: 737-45.
72. Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 2010; 194: 1470-8.
73. Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol 2008; 26: 2155-61.
74. McKinley ET, Bugaj JE, Zhao P, et al. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin Cancer Res 2011; 17: 3332-40.
75. Benz MR, Herrmann K, Walter F, et al. (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med 2011; 52: 1684-9.
76. Revheim ME, Winge-Main AK, Hagen G, Fjeld JG, Fosså SD, Lilleby W. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol) 2011; 23: 339-43.
77. Dunphy MP, Lewis JS. Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J Nucl Med 2009; 50 Suppl 1: 106S-21S.
78. Chen W, Delaloye S, Silverman DH, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007; 25: 4714-21.
79. Sohn HJ, Yang YJ, Ryu JS, et al. [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 2008; 14: 7423-9.
80. Zhang CC, Yan Z, Li W, et al. [(18)F]FLT-PET imaging does not always "light up" proliferating tumor cells. Clin Cancer Res 2012; 18: 1303-12.
81. Pressman D. The development and use of radiolabeled antitumor antibodies. Cancer Res 1980; 40: 2960-4.
82. Divgi CR, Welt S, Kris M, et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 1991; 83: 97-104.
83. Tolmachev V, Orlova A, Lundqvist H. Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides. Curr Med Chem 2003; 10: 2447-60
84. Brouwers A, Verel I, Van Eerd J, et al. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother Radiopharm 2004; 19: 155-63.
85. Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007; 48: 1313-9.
86. Dijkers EC, Kosterink JG, Rademaker AP, et al. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 2009; 50: 974-81.
87. Behr TM, Béhé M, Wörmann B. Trastuzumab and breast cancer. N Engl J Med 2001 27; 345: 995-6.
88. Milenic DE, Wong KJ, Baidoo KE, et al. Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials. MAbs 2010; 2: 550-64.
89. Lub-de Hooge MN, Kosterink JG, Perik PJ, et al. Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol 2004; 143: 99-106.
90. McLarty K, Cornelissen B, Scollard DA, Done SJ, Chun K, Reilly RM. Associations between the uptake of 111In-DTPAtrastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging.2009; 36: 81-93.
91. de Korte MA, de Vries EG, Lub-de Hooge MN, et al. 111Indiumtrastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 2007; 43: 2046-51.
92. Perik PJ, Lub-De Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006; 24: 2276-82.
93. Pagani M, Stone-Elander S, Larsson SA. Alternative positron emission tomography with non-conventional positron emitters: effects of their physical properties on image quality and potential clinical applications. Eur J Nucl Med 1997; 24: 1301-27.
94. Bakir MA, Eccles S, Babich JW, et al. c-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies. J Nucl Med 1992; 33: 2154-60.
95. Bruskin A, Sivaev I, Persson M, et al. Radiobromination of monoclonal antibody using potassium [76Br] (4 isothiocyanatobenzylammonio)-bromo-decahydro-closo-dodecaborate (Bromo-DABI). Nucl Med Biol 2004; 31: 205-11.
96. Winberg KJ, Persson M, Malmström PU, Sjöberg S, Tolmachev V. Radiobromination of anti-HER2/neu/ErbB-2 monoclonal antibody using the p-isothiocyanatobenzene derivative of the [76Br]undecahydro-bromo-7,8-dicarba-nido-undecaborate(1-) ion. Nucl Med Biol 2004; 31: 425-33.
97. Mume E, Orlova A, Malmström PU, Lundqvist H, Sjöberg S, Tolmachev V. Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET. Nucl Med Biol 2005; 32: 613-22.
98. Garmestani K, Milenic DE, Plascjak PS, Brechbiel MW. A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin. Nucl Med Biol 2002; 29: 599-606.
99. Niu G, Li Z, Xie J, Le QT, Chen X. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med 2009; 50: 1116-23.
100. Orlova A, Wållberg H, Stone-Elander S, Tolmachev V. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 2009; 50: 417-25.
101. Nayak TK, Regino CA, Wong KJ, et al. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A"-DTPAcetuximab. Eur J Nucl Med Mol Imaging 2010; 37: 1368-76.
102. Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 2007; 34: 850-8.
103. Ping Li W, Meyer LA, Capretto DA, Sherman CD, Anderson CJ. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growthfactor receptor-positive tumors. Cancer Biother Radiopharm 2008; 23: 158-71
104. Eiblmaier M, Meyer LA, Watson MA, Fracasso PM, Pike LJ, Anderson CJ. Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines. J Nucl Med 2008; 49: 1472-9.
105. Achmad A, Hanaoka H, Yoshioka H, et al. Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography. Cancer Sci 2012; 103: 600-5.
106. Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW. Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma. J Nucl Med 2010; 51: 942-50.
107. Nayak TK, Garmestani K, Milenic DE, Baidoo KE, Brechbiel MW. HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts. PLoS One 2011; 6: e18198.
108. Paudyal B, Paudyal P, Oriuchi N, Hanaoka H, Tominaga H, Endo K. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts. Cancer Sci 2011; 102: 117-21.
109. Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW. PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-Aβ-DTPA-bevacizumab. Int J Cancer 2011; 128: 920-6.
110. Niu G, Li Z, Cao Q, Chen X. Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab. Eur J Nucl Med Mol Imaging 2009; 36: 1510-9.
111. Verel I, Visser GW, van Dongen GA. The promise of immuno-PET in radioimmunotherapy. J Nucl Med 2005; 46 Suppl 1: 164S-71S.
112. van Dongen GA, Visser GW, Lub-de Hooge MN, de Vries EG, Perk LR. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist.2007; 12: 1379-89.
113. van Dongen GA, Poot AJ, Vugts DJ. PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumour Biol 2012; 33: 607-15.
114. Verel I, Visser GW, Boerman OC, et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm 2003; 18: 655-61.
115. Verel I, Visser GW, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GA. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med 2003; 44: 1271-81.
116. Vosjan MJ, Perk LR, Visser GW, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyldesferrioxamine. Nat Protoc 2010; 5(4): 739-43
117. Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010; 87: 586-92.
118. Gaykema SB, Brouwers AH, Hovenga S, Lub-de Hooge MN, de Vries EG, Schröder CP. Zirconium-89-trastuzumab positron emission tomography as a tool to solve a clinical dilemma in a patient with breast cancer. J Clin Oncol 2012; 30: e74-5.
119. Aerts HJ, Dubois L, Perk L, et al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 2009; 50: 123-31.
120. Nagengast WB, de Korte MA, Oude Munnink TH, et al. 89Zrbevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med 2010; 51: 761-7.
121. Perk LR, Stigter-van Walsum M, Visser GW, et al. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging 2008; 35: 1857-67.
122. Oude Munnink TH, Arjaans ME, Timmer-Bosscha H, et al. PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models. J Nucl Med 2011; 52: 2001-8.
123. Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, et al. ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J Nucl Med 2010; 51: 1565-72.
124. Fleuren ED, Versleijen-Jonkers YM, van de Luijtgaarden AC, et al. Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507. Clin Cancer Res 2011; 17: 7693-703.
125. Holland JP, Caldas-Lopes E, Divilov V, et al. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu ex pression in mice using Zr-DFO-trastuzumab. PLoS One 2010; 5: e8859.
126. Oude Munnink TH, Korte MA, Nagengast WB, et al. (89)Zrtrastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur J Cancer 2010; 46: 678-84.
127. Nagengast WB, Hooge MN, van Straten EM, et al. VEGF-SPECT with In-bevacizumab in stage III/IV melanoma patients. Eur J Cancer 2011; 47: 1595-602.
128. Desar IM, Stillebroer AB, Oosterwijk E, et al. 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib. J Nucl Med 2010; 51: 1707-15
129. Scheer MG, Stollman TH, Boerman OC, et al. Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: Lack of correlation with VEGF-A expression. Eur J Cancer 2008; 44: 1835-40.
130. Reilly RM, Sandhu J, Alvarez-Diez TM, Gallinger S, Kirsh J, Stern H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 1995; 28: 126-42.
131. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992; 52: 3402-8.
132. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004; 22: 701-6.
133. Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med 2006; 47: 793-6.
134. Tang Y, Wang J, Scollard DA, et al. Imaging of HER2/neupositive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragments. Nucl Med Biol 2005; 32: 51-8.
135. Tang Y, Scollard D, Chen P, Wang J, Holloway C, Reilly RM. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [99mTc]-HYNICtrastuzumab (Herceptin) Fab fragments. Nucl Med Commun 2005; 26: 427-32.
136. Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, et al. Optimization of IGF-1R SPECT/CT Imaging Using (111)In-Labeled F(ab')(2) and Fab Fragments of the Monoclonal Antibody R1507. Mol Pharm 2012 Jul 13. [Epub ahead of print]
137. Yoshida C, Tsuji AB, Sudo H, et al. Development of positron emission tomography probe of 64Cu-labeled anti-C-kit 12A8 Fab to measure protooncogene C-kit expression. Nucl Med Biol 2011; 38: 331-7.
138. Wester HJ, Kessler H. Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? J Nucl Med 2005; 46: 1940-5.
139. Vaneycken I, D'huyvetter M, Hernot S, et al. Immuno-imaging using nanobodies. Curr Opin Biotechnol.2011; 22: 877-81.
140. Vaneycken I, Devoogdt N, Van Gassen N, et al. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J 2011; 25: 2433-46.
141. Huang L, Gainkam LO, Caveliers V, et al. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol 2008; 10: 167-75.
142. Gainkam LO, Huang L, Caveliers V, et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med 2008; 49: 788-95.
143. Gainkam LO, Keyaerts M, Caveliers V, et al. Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: a tool for noninvasive monitoring of tumor response to therapy. Mol Imaging Biol 2011; 13: 940-8.
144. Levashova Z, Backer MV, Horng G, Felsher D, Backer JM, Blankenberg FG. SPECT and PET imaging of EGF receptors with sitespecifically labeled EGF and dimeric EGF. Bioconjug Chem 2009; 20: 742-9.
145. Sundberg AL, Orlova A, Bruskin A, et al. [(111)In]Bz-DTPAhEGF: Preparation and in vitro characterization of a potential antiglioblastoma targeting agent. Cancer Biother Radiopharm 2003; 18: 643-54.
146. Velikyan I, Sundberg AL, Lindhe O, et al. Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med 2005; 46: 1881-8.
147. Cuartero-Plaza A, Martínez-Miralles E, Rosell R, Vadell-Nadal C, Farré M, Real FX. Radiolocalization of squamous lung carcinoma with 131I-labeled epidermal growth factor. Clin Cancer Res 1996; 2: 13-20.
148. Rusckowski M, Qu T, Chang F, Hnatowich DJ. Technetium-99m labeled epidermal growth factor-tumor imaging in mice. J Pept Res 1997; 50: 393-401.
149. Capala J, Barth RF, Bailey MQ, Fenstermaker RA, Marek MJ, Rhodes BA. Radiolabeling of epidermal growth factor with 99mTc and in vivo localization following intracerebral injection into normal and glioma-bearing rats. Bioconjug Chem 1997; 8: 289-95.
150. Cornelissen B, Kersemans V, Burvenich I, et al. Synthesis, biodistribution and effects of farnesyltransferase inhibitor therapy on tumour uptake in mice of 99mTc labelled epidermal growth factor. Nucl Med Commun 2005; 26: 147-53.
151. Reilly RM, Kiarash R, Sandhu J, et al. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. J Nucl Med 2000; 41: 903-11.
152. Orlova A, Bruskin A, Sjöström A, Lundqvist H, Gedda L, Tolmachev V. Cellular processing of (125)I-and (111)in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells. Nucl Med Biol 2000; 27: 827-35
153. Li W, Niu G, Lang L, et al. PET imaging of EGF receptors using [18F]FBEM-EGF in a head and neck squamous cell carcinoma model. Eur J Nucl Med Mol Imaging 2012; 39: 300-8.
154. Tolmachev V, Orlova A, Wei Q, Bruskin A, Carlsson J, Gedda L. Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice. Cancer Biother Radiopharm 2004; 19: 491-501.
155. Hu M, Scollard D, Chan C, Chen P, Vallis K, Reilly RM. Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF. Nucl Med Biol 2007; 34: 887-96.
156. Sandström K, Haylock AK, Velikyan I, et al. Improved tumor-toorgan ratios of a novel 67Ga-human epidermal growth factor radionuclide conjugate with preadministered antiepidermal growth factor receptor affibody molecules. Cancer Biother Radiopharm 2011; 26: 593-601.
157. Cai W, Chen K, Mohamedali KA, et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med 2006; 47: 2048-56.
158. Backer MV, Levashova Z, Patel V, et al. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med 2007; 13: 504-9.
159. Blankenberg FG, Levashova Z, Sarkar SK, Pizzonia J, Backer MV, Backer JM. Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study. Transl Oncol.2010; 3: 56-64.
160. Levashova Z, Backer M, Hamby CV, Pizzonia J, Backer JM, Blankenberg FG. Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors. J Nucl Med 2010; 51: 959-66.
161. Lee I, Yoon KY, Kang CM, et al. Evaluation of the angiogenesis inhibitor KR-31831 in SKOV-3 tumor-bearing mice using (64)Cu-DOTA-VEGF(121) and microPET. Nucl Med Biol 2012; 39: 840-6.
162. Sun BF, Kobayashi H, Le N, et al. Biodistribution of 125I-labeled des(1-3) insulin-like growth factor I in tumor-bearing nude mice and its in vitro catabolism. Cancer Res 1997; 57: 2754-9.
163. Sun BF, Kobayashi H, Le N, et al. Effects of insulin-like growth factor binding proteins on insulinlike growth factor-I biodistribution in tumor-bearing nude mice. J Nucl Med 2000; 41: 318-26.
164. Cornelissen B, McLarty K, Kersemans V, Reilly RM. The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin). Nucl Med Biol 2008; 35: 645-53.
165. Rothe A, Hosse RJ, Power BE. In vitro display technologies reveal novel biopharmaceutics. FASEB J 2006; 20: 1599-610.
166. Deutscher SL. Phage display in molecular imaging and diagnosis of cancer. Chem Rev 2010; 110: 3196-211.
167. Karasseva NG, Glinsky VV, Chen NX, Komatireddy R, Quinn TP. Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library. J Protein Chem 2002; 21: 287-96.
168. Kumar SR, Quinn TP, Deutscher SL. Evaluation of an 111Inradiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor expressing breast carcinomas. Cancer Res 2007; 13: 6070-9.
169. Kumar SR, Gallazzi FA, Ferdani R, Anderson CJ, Quinn TP, Deutscher SL. In vitro and in vivo evaluation of 64Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas. Cancer Biother Radiopharm 2010; 25: 693-703.
170. Denholt CL, Binderup T, Stockhausen MT, et al. Evaluation of 4-[18F]fluorobenzoyl-FALGEA-NH2 as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer. Nucl Med Biol 2011; 38: 509-15.
171. Shrivastava A, von Wronski MA, Sato AK, et al. A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases. Protein Eng Des Sel 2005: 417-24.
172. Miao Z, Levi J, Cheng Z. Protein scaffold-based molecular probes for cancer molecular imaging. Amino Acids 2011; 41: 1037-47
173. Nygren PA, Uhlén M. Scaffolds for engineering novel binding sites in proteins. Curr Opin Struct Biol 1997; 7: 463-9.
174. Binz HK, Amstutz P, Plückthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 2005; 23: 1257-68.
175. Hey T, Fiedler E, Rudolph R, Fiedler M. Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. Trends Biotechnol 2005; 23: 514-22.
176. Skerra A. Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol 2007; 18: 295-304.
177. Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Ståhl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010; 584: 2670-80.
178. Grabulovski D, Kaspar M, Neri D. A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties. J Biol Chem 2007: 282: 3196-204.
179. Miao Z, Ren G, Liu H, et al. An engineered knottin peptide labeled with 18F for PET imaging of integrin expression. Bioconjug Chem 2009; 20: 2342-7.
180. Jiang L, Miao Z, Kimura RH, et al. 111In-labeled cystine-knot peptides based on the Agouti-related protein for targeting tumor angiogenesis. J Biomed Biotechnol 2012; 2012: 368075.
181. Zahnd C, Kawe M, Stumpp MT, et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 2010; 70: 1595-605.
182. Nygren PA. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J 2008; 275: 2668-76.
183. Wikman M, Steffen AC, Gunneriusson E, et al. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng Des Sel.2004; 17: 455-62.
184. Orlova A, Magnusson M, Eriksson TL, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 2006; 66: 4339-48.
185. Tolmachev V, Rosik D, Wållberg H, et al. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR: 2377 Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging 2010; 37: 613-22.
186. Tolmachev V, Malmberg J, Hofström C, et al. Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTA-ZIGF1R: 4551. J Nucl Med 2012; 53: 90-7.
187. Lindborg M, Cortez E, Höidén-Guthenberg I, et al. Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor β in vivo. J Mol Biol 2011; 407: 298-315.
188. Kronqvist N, Malm M, Göstring L, et al. Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules. Protein Eng Des Sel.2011; 24: 385-96.
189. Orlova A, Rosik D, Sandström M, Lundqvist H, Einarsson L, Tolmachev V. Evaluation of [(111/114m)In]CHX-A"-DTPA-ZHER2: 342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors. Q J Nucl Med Mol Imaging 2007; 51: 314-23.
190. Kramer-Marek G, Shenoy N, Seidel J, Griffiths GL, Choyke P, Capala J. 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET. Eur J Nucl Med Mol Imaging 2011; 38: 1967-76.
191. Wållberg H, Orlova A, Altai M, et al. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties. J Nucl Med 2011; 52: 461-9.
192. Malmberg J, Sandström M, Wester K, Tolmachev V, Orlova A. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In-and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody. Nucl Med Biol 2011; 38: 1093-102.
193. Orlova A, Tolmachev V, Pehrson R, et al. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 2007; 67: 2178-86.
194. Ahlgren S, Orlova A, Wållberg H, et al. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J Nucl Med 2010; 51: 1131-8.
195. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des 2008; 14: 2999-3019.
196. Tolmachev V, Stone-Elander S, Orlova A. Radiolabelled receptortyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol 2010; 11: 992-1000.
197. Wållberg H, Orlova A. Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2: 342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm 2008; 23: 435-42.
198. Steffen AC, Wikman M, Tolmachev V, Adams GP, Nilsson FY, Ståhl S, Carlsson J. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biother Radiopharm 2005; 20: 239-48.
199. Steffen AC, Orlova A, Wikman M, et al. Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. Eur J Nucl Med Mol Imaging 2006; 33: 631-8.
200. Tolmachev V, Mume E, Sjöberg S, Frejd FY, Orlova A. Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. Eur J Nucl Med Mol Imaging 2009; 36: 692-701.
201. Cheng Z, De Jesus OP, Namavari M, et al. Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J Nucl Med 2008; 49: 804-13.
202. Cheng Z, De Jesus OP, Kramer DJ, et al. 64Cu-labeled affibody molecules for imaging of HER2 expressing tumors. Mol Imaging Biol 2010; 12: 316-24.
203. Tolmachev V, Friedman M, Sandström M, et al. Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J Nucl Med 2009; 50: 274-83
204. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009; 8: 2861-71.
205. Tolmachev V, Tran TA, Rosik D, Sjöberg A, Abrahmsén L, Orlova A. Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition. J Nucl Med 2012; 53: 953-60.
206. Arora P, OasTG, Myers JK. Fast andfaster: a designed variant of the Bdomain of protein A folds in 3 microsec. Protein Sci 2004; 13: 847-53.
207. Tolmachev V, Velikyan I, Sandström M, Orlova A. A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue. Eur J Nucl Med Mol Imaging 2010; 37: 1356-67
208. Tran T, Engfeldt T, Orlova A, et al. (99m)Tc-maEEE-Z(HER2: 342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjug Chem 2007; 18: 1956-64.
209. Heskamp S, Laverman P, Rosik D, et al. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2: 2395 in a mouse model for ovarian cancer. J Nucl Med 2012; 53: 146-53.
210. Engfeldt T, Renberg B, Brumer H, Nygren PA, Karlström AE. Chemical synthesis of triple-labelled three-helix bundle binding proteins for specific fluorescent detection of unlabelled protein. Chembiochem 2005; 6: 1043-50.
211. Engfeldt T, Tran T, Orlova A, et al. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. Eur J Nucl Med Mol Imaging 2007; 34: 1843-53.
212. Ekblad T, Tran T, Orlova A, et al. Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging 2008; 35: 2245-55.
213. Orlova A, Tran TA, Ekblad T, Karlström AE, Tolmachev V. (186)Re-maSGS-Z (HER2: 342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. Eur J Nucl Med Mol Imaging 2010; 37: 260-9.
214. Malmberg J, Perols A, Varasteh Z, et al. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts. Eur J Nucl Med Mol Imaging 2012; 39: 481-92.
215. Perols A, Honarvar H, Strand J, et al. Influence of DOTA chelator position on biodistribution and targeting properties of (111)Inlabelled synthetic anti-HER2 affibody molecules. Bioconjug Chem 2012; 23: 1661-70.
216. Ahlgren S, Orlova A, Rosik D, Sandström M, Sjöberg A, Baastrup B. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant Affibody molecules. Bioconjug Chem 2008; 19: 235-43.
217. Tolmachev V, Xu H, Wållberg H, Ahlgren S, Hjertman M, Sjöberg A. Evaluation of a maleimido derivative of CHX-A" DTPA for site-specific labeling of affibody molecules. Bioconjug Chem 2008; 19: 1579-87.
218. Miao Z, Ren G, Liu H, Jiang L, Cheng Z. Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein. Bioconjug Chem 2010; 21: 947-54.
219. Wållberg H, Ahlgren S, Widström C, Orlova A. Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-Z HER2: 2395(-Cys) affibody molecule for targeting of HER2-expressing tumors. Mol Imaging Biol 2010; 12: 54-62
220. Tolmachev V, Altai M, Sandstrom M, et al. Evaluation of a Maleimido Derivative of NOTA for Site-Specific Labeling of Affibody Molecules. Bioconjug Chem 2011; 22: 894-902.
221. Altai M, Perols A, Karlström AE, et al. Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA. Nucl Med Biol 2012; 39: 518-29.
222. Kramer-Marek G, Kiesewetter DO, Martiniova L, Jagoda E, Lee SB, Capala J. [18F]FBEM-Z(HER2: 342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 2008; 35: 1008-18.
223. Mume E, Orlova A, Larsson B, Nilsson AS, Nilsson FY, Sjöberg S, Tolmachev V. Evaluation of (4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. Bioconjug Chem 2005; 16: 1547-55.
224. Ahlgren S, Wållberg H, Tran TA, et al. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2: 2395, with C-terminally engineered cysteine. J Nucl Med 2009; 50: 781-9.
225. Tran TA, Rosik D, Abrahmsén L, et al. Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging. Eur J Nucl Med Mol Imaging 2009; 36: 1864-73.
226. Altai M, Wållberg H, Orlova A, et al. Order of amino acids in Cterminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules. Amino Acids 2012; 42: 1975-85.
227. Tolmachev V, Hofström C, Malmberg J, et al. HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [99(m)Tc(CO)3](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation. Bioconjug Chem 2010; 21: 2013-22.
228. Hofstrom C, Orlova A, Altai M, Wangsell F, Graslund T, Tolmachev V. Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules sitespecifically labeled with (99m)Tc, (111)In, and (125)I. J Med Chem 2011; 54: 3817-26.
229. Tolmachev V, Wållberg H, Sandström M, Hansson M, Wennborg A, Orlova A. Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur J Nucl Med Mol Imaging 2011; 38: 531-9.
230. Kramer-Marek G, Kiesewetter DO, Capala J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules. J Nucl Med 2009; 50: 1131-9.
231. Kramer-Marek G, Gijsen M, Kiesewetter DO, et al. Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model. J Nucl Med 2012; 53: 629-37.
232. Baum RP, Prasad V, Müller D, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled affibody molecules. J Nucl Med 2010; 51: 892-7.
233. Feldwisch J, Tolmachev V, Lendel C, et al. Design of an optimized scaffold for affibody molecules. J Mol Biol 2010; 398: 232-47
234. Sandberg D, Wennborg A, Feldwisch F, et al. First clinical observations of HER2 specific [111In]ABY-025 metastatic detection capability in females with metastatic breast cancer. J Nucl Med 2012; 53 (Supplement 1): 220
235. Binz HK, Amstutz P, Kohl A, et al. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 2004; 22: 575-82.
236. Steiner D, Forrer P, Plückthun A. Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display. J Mol Biol 2008; 382: 1211-27.
237. Hackel BJ, Kimura RH, Gambhir SS. Use of (64)Cu-labeled fibronectin domain with EGFR-overexpressing tumor xenograft: molecular imaging. Radiology 2012; 263: 179-88.
238. Koide A, Koide S. Monobodies: antibody mimics based on the scaffold of the fibronectintype III domain. Methods Mol Biol 2007; 352: 95-109.
239. Hackel BJ, Ackerman ME, Howland SW, Wittrup KD. Stability and CDR composition biases enrich binder functionality landscapes. J Mol Biol 2010; 401: 84-96.
240. Slobbe P, Poot AJ, Windhorst AD, van Dongen GA. PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET. Drug Discov Today 2012 Jul 2. [Epub ahead of print]
241. Memon AA, Jakobsen S, Dagnaes-Hansen F, Sorensen BS, Keiding S, Nexo E. Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res 2009; 69: 873-8.
242. Samén E, Thorell JO, Lu L, Tegnebratt T, Holmgren L, Stone-Elander S. Synthesis and preclinical evaluation of [(11)C]PAQ as a PET imaging tracer for VEGFR-2. Eur J Nucl Med Mol Imaging 2009; 36: 1283-95.
243. Meng X, Loo BW Jr, Ma L, Murphy JD, Sun X, Yu J. Molecular imaging with 11C-PD153035 PET/CT predicts survival in nonsmall cell lung cancer treated with EGFR-TKI: a pilot study. J Nucl Med 2011; 52: 1573-9.
244. Gelovani JG. Molecular imaging of epidermal growth factor receptor expression-activity at the kinase level in tumors with positron emission tomography. Cancer Metastasis Rev 2008; 27: 645-53.
245. Fredriksson A, Johnström P, Thorell JO, et al. In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants. Life Sci 1999; 65: 165-74.
246. Wang H, Yu J, Yang G, et al. Assessment of 11C-labeled-4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression. Cancer Sci 2007; 98: 1413-6.
247. Veach DR, Namavari M, Pillarsetty N, et al. Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib. J Med Chem 2007; 50: 5853-7.
248. Zhang MR, Kumata K, Hatori A, et al. [11C]Gefitinib ([11c]Iressa): radiosynthesis, in vitro uptake, and in vivo imaging of intact murine fibrosarcoma. Mol Imaging Biol 2010; 12: 181-91.
249. Samén E, Thorell JO, Fredriksson A, Stone-Elander S. The tyrosine kinase inhibitor PD153035: implication of labeling position on radiometabolites formed in vitro. Nucl Med Biol 2006; 33: 1005-11.
250. Pal A, Balatoni JA, Mukhopadhyay U, et al. Radiosynthesis and initial in vitro evaluation of [18F]F-PEG6-IPQA--a novel PET radiotracer for imaging EGFR expression-activity in lung carcinomas. Mol Imaging Biol 2011; 13: 853-61.
251. Doubrovin M, Kochetkova T, Santos E, et al. (124)Iiodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo. J Nucl Med 2010; 51: 121-9.
252. Pal A, Glekas A, Doubrovin M, et al. Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol 2006; 8: 262-77.
253. Su H, Seimbille Y, Ferl GZ, et al. Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging 2008; 35: 1089-99.
254. Brehmer D, Greff Z, Godl K, et al. Cellular targets of gefitinib. Cancer Res 2005; 65: 379-82.